ClinicaliQ Trial Snapshot
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) — Recruiting • Phase I • Oncology • NCT06843447.
- What is being tested: Raludotatug deruxtecan (MK-5909-003), a novel targeted therapy being investigated for treating relapsed high-grade serous ovarian cancer—a particularly aggressive form that has recurred after initial treatment.
- Patient eligibility overview: The trial recruits patients with confirmed relapsed high-grade serous ovarian cancer; specific inclusion/exclusion criteria would typically encompass prior treatment history, organ function, and performance status requirements.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a…
Eligibility Snapshot
- : * Has pathologically documented diagnosis of high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer * Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1 * Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) * Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.